Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3908 - Causes of death statistics underestimate the burden of head and neck (H&N) cancers: a nationwide study from France in 2008-2012 (EPICORL study)

Date

09 Oct 2016

Session

Poster display

Presenters

Caroline Even

Citation

Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376

Authors

C. Even1, Y. Pointreau2, L. Geoffrois3, M. Schwarzinger4, M. Bec5, C. Godard5, F. Huguet6, S. Témam7, S.P. Thiébaut4

Author affiliations

  • 1 Medical Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 2 Oncology, Centre Jean Bernard, Le Mans/FR
  • 3 Medical Oncology, Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy/FR
  • 4 Epidemiology, THEN (Translational Health Economics Network), Paris/FR
  • 5 Market Access, MSD, Courbevoie/FR
  • 6 Department Of Radiation Oncology, Tenon Hospital, Paris/FR
  • 7 Surgical Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
More

Resources

Abstract 3908

Background

Patients with H&N cancer carry the highest risk of secondary primary cancers. Determining the underlying cause of death is conflicting in presence of multiple primary cancer sites, and the actual burden of H&N cancers may be underestimated by causes of death statistics.

Methods

Using the French National Hospital Discharge (PMSI) database, we identified all adult patients residing in Metropolitan France and diagnosed with H&N cancer (ICD-10: C00-C06; C09-C14; C30.0; C31; C32) in 2008-2012. Overall death was ascertained from in-hospital mortality with use of imputation methods to estimate death outside hospital in 2008-2012. Among deceased patients, we considered advanced H&N cancer (stage III/IV at diagnosis or relapse in the follow-up) as a cause of death. A competing cause of death from other primary cancer sites was categorized according to its timing relative to the index date of H&N cancer: former (180 days) cancers. Study results were compared to National causes of death statistics (CEPIDC) with use of the same ICD-10 definitions.

Results

Of 131,965 French patients identified with H&N cancer in 2008-2012, 58,562 (44.4%) died in the same period including 46,463 (79.3%) deaths recorded at hospital. Of 58,562 deceased patients, 50,910 (86.9%) were recorded with advanced H&N cancer and involved 82.4% male patients at a median (IQR) age of 64 (57-74) at death. Overall, 20,926 (41.1%) patients had another primary cancer site than H&N cancer recorded before death: 4,751 (9.3%) former, 11,030 (21.7%) synchronous, and 5,145 (10.1%) metachronous cancers were recorded with increasing likelihood to be considered as the underlying cause of death. The death toll of H&N cancers represented 0.96% of all-cause mortality (2.65% of all premature deaths before 65 years old) in France and increased annually by 6.1% on average. In National causes of death statistics, only 25,647 deaths were attributed to H&N cancers in 2008-2012 without time trends.

Conclusions

The study results suggest that National causes of death statistics underestimate the burden of H&N cancer. It may be explain by the frequency of secondary primary cancers.

Clinical trial identification

Legal entity responsible for the study

THEN (Translational Health Economics Network)

Funding

MSD France

Disclosure

C. Even, Y. Pointreau, L. Geoffrois, M. Schwarzinger, F. Huguet, S. Témam, S.P. Thiébaut: Corporate-sponsored research. M. Bec, C. Godard: MSD employee.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings